592 related articles for article (PubMed ID: 31679042)
21. Chromosome 1q gain and tenascin-C expression are candidate markers to define different risk groups in pediatric posterior fossa ependymoma.
Araki A; Chocholous M; Gojo J; Dorfer C; Czech T; Heinzl H; Dieckmann K; Ambros IM; Ambros PF; Slavc I; Haberler C
Acta Neuropathol Commun; 2016 Aug; 4(1):88. PubMed ID: 27550150
[TBL] [Abstract][Full Text] [Related]
22. Biology and management of ependymomas.
Wu J; Armstrong TS; Gilbert MR
Neuro Oncol; 2016 Jul; 18(7):902-13. PubMed ID: 27022130
[TBL] [Abstract][Full Text] [Related]
23. Ependymomas of the spinal region in adults: Clinical and pathological features and MYCN expression levels in spinal ependymomas and myxopapillary ependymomas.
Topel G; Dirilenoğlu F; Sevin İE; Kahraman A
Ann Diagn Pathol; 2024 Jun; 70():152299. PubMed ID: 38555652
[TBL] [Abstract][Full Text] [Related]
24. Indications for a tumor suppressor gene at 22q11 involved in the pathogenesis of ependymal tumors and distinct from hSNF5/INI1.
Kraus JA; de Millas W; Sörensen N; Herbold C; Schichor C; Tonn JC; Wiestler OD; von Deimling A; Pietsch T
Acta Neuropathol; 2001 Jul; 102(1):69-74. PubMed ID: 11547953
[TBL] [Abstract][Full Text] [Related]
25. Transcriptional profiling of paediatric ependymomas identifies prognostically significant groups.
Łastowska M; Matyja E; Sobocińska A; Wojtaś B; Niemira M; Szałkowska A; Krętowski A; Karkucińska-Więckowska A; Kaleta M; Ejmont M; Tarasińska M; Perek-Polnik M; Dembowska-Bagińska B; Pronicki M; Grajkowska W; Trubicka J
J Pathol Clin Res; 2021 Nov; 7(6):565-576. PubMed ID: 34314101
[TBL] [Abstract][Full Text] [Related]
26. Specific chromosomal imbalances as detected by array CGH in ependymomas in association with tumor location, histological subtype and grade.
Rousseau A; Idbaih A; Ducray F; Crinière E; Fèvre-Montange M; Jouvet A; Delattre JY
J Neurooncol; 2010 May; 97(3):353-64. PubMed ID: 19865800
[TBL] [Abstract][Full Text] [Related]
27. Telomerase activation in posterior fossa group A ependymomas is associated with dismal prognosis and chromosome 1q gain.
Gojo J; Lötsch D; Spiegl-Kreinecker S; Pajtler KW; Neumayer K; Korbel P; Araki A; Brandstetter A; Mohr T; Hovestadt V; Chavez L; Kirchhofer D; Ricken G; Stefanits H; Korshunov A; Pfister SM; Dieckmann K; Azizi AA; Czech T; Filipits M; Kool M; Peyrl A; Slavc I; Berger W; Haberler C
Neuro Oncol; 2017 Sep; 19(9):1183-1194. PubMed ID: 28371821
[TBL] [Abstract][Full Text] [Related]
28. Genomic characterization of ependymomas reveals 6q loss as the most common aberration.
Olsen TK; Gorunova L; Meling TR; Micci F; Scheie D; Due-Tønnessen B; Heim S; Brandal P
Oncol Rep; 2014 Aug; 32(2):483-90. PubMed ID: 24939246
[TBL] [Abstract][Full Text] [Related]
29. Review of ependymomas: assessment of consensus in pathological diagnosis and correlations with genetic profiles and outcome.
Sasaki A; Hirato J; Hirose T; Fukuoka K; Kanemura Y; Hashimoto N; Kodama Y; Ichimura K; Sakamoto H; Nishikawa R
Brain Tumor Pathol; 2019 Apr; 36(2):92-101. PubMed ID: 30929114
[TBL] [Abstract][Full Text] [Related]
30. Histological spectrum of ependymomas and correlation of p53 and Ki-67 expression with ependymoma grade and subtype.
Suri VS; Tatke M; Singh D; Sharma A
Indian J Cancer; 2004; 41(2):66-71. PubMed ID: 15318011
[TBL] [Abstract][Full Text] [Related]
31. Immunohistochemical analysis of H3K27me3 demonstrates global reduction in group-A childhood posterior fossa ependymoma and is a powerful predictor of outcome.
Panwalkar P; Clark J; Ramaswamy V; Hawes D; Yang F; Dunham C; Yip S; Hukin J; Sun Y; Schipper MJ; Chavez L; Margol A; Pekmezci M; Chung C; Banda A; Bayliss JM; Curry SJ; Santi M; Rodriguez FJ; Snuderl M; Karajannis MA; Saratsis AM; Horbinski CM; Carret AS; Wilson B; Johnston D; Lafay-Cousin L; Zelcer S; Eisenstat D; Silva M; Scheinemann K; Jabado N; McNeely PD; Kool M; Pfister SM; Taylor MD; Hawkins C; Korshunov A; Judkins AR; Venneti S
Acta Neuropathol; 2017 Nov; 134(5):705-714. PubMed ID: 28733933
[TBL] [Abstract][Full Text] [Related]
32. Correlation of bcl-2, p53, and MIB-1 expression with ependymoma grade and subtype.
Rushing EJ; Brown DF; Hladik CL; Risser RC; Mickey BE; White CL
Mod Pathol; 1998 May; 11(5):464-70. PubMed ID: 9619600
[TBL] [Abstract][Full Text] [Related]
33. Comprehensive profiling of myxopapillary ependymomas identifies a distinct molecular subtype with relapsing disease.
Bockmayr M; Harnisch K; Pohl LC; Schweizer L; Mohme T; Körner M; Alawi M; Suwala AK; Dorostkar MM; Monoranu CM; Hasselblatt M; Wefers AK; Capper D; Hench J; Frank S; Richardson TE; Tran I; Liu E; Snuderl M; Engertsberger L; Benesch M; von Deimling A; Obrecht D; Mynarek M; Rutkowski S; Glatzel M; Neumann JE; Schüller U
Neuro Oncol; 2022 Oct; 24(10):1689-1699. PubMed ID: 35380708
[TBL] [Abstract][Full Text] [Related]
34. The clinical features and surgical outcomes of intracranial tanycytic ependymomas: a single-institutional experience.
Tao X; Dong J; Hou Z; Hao S; Zhang Q; Wu Z; Zhang J; Liu B
J Neurooncol; 2017 Sep; 134(2):339-347. PubMed ID: 28653235
[TBL] [Abstract][Full Text] [Related]
35. Molecular genetics of ependymomas and pediatric diffuse gliomas: a short review.
Nobusawa S; Hirato J; Yokoo H
Brain Tumor Pathol; 2014 Oct; 31(4):229-33. PubMed ID: 25182241
[TBL] [Abstract][Full Text] [Related]
36. L1CAM Immunopositivity in Anaplastic Supratentorial Ependymomas: Correlation With Clinical and Histological Parameters.
Chavali P; Rao S; Palavalasa S; Bevinahalli N; Muthane YTC; Sadashiva N; Santosh V
Int J Surg Pathol; 2019 May; 27(3):251-258. PubMed ID: 30251576
[TBL] [Abstract][Full Text] [Related]
37. [Intracranial ependymomas in adult patients. Diagnosis and histological prognostic factors].
Figarella-Branger D; Metellus P; Barrié M; Maues de Paula A; Fernandez C; Polivka M; Vital A; Labrousse F; Vignaud JM; Laquerrière A; Rousselet MC; Lacroix C; Saikali S; Chapon F; Gontier MF; Chrétien F; Babin P; Rigau V; Vandenbos F; Peoc'h M; Kujas M; Chinot O; Gouvernet J; Giorgi R; Guyotat J; Jouvet A
Neurochirurgie; 2007 Jun; 53(2-3 Pt 1):76-84. PubMed ID: 17445840
[TBL] [Abstract][Full Text] [Related]
38. MRI Phenotype of RELA-fused Pediatric Supratentorial Ependymoma.
Nowak J; Jünger ST; Huflage H; Seidel C; Hohm A; Vandergrift LA; von Hoff K; Rutkowski S; Pietsch T; Warmuth-Metz M
Clin Neuroradiol; 2019 Dec; 29(4):595-604. PubMed ID: 30027327
[TBL] [Abstract][Full Text] [Related]
39. Clinical significance of the histological and molecular characteristics of ependymal tumors: a single institution case series from China.
Xi S; Sai K; Hu W; Wang F; Chen Y; Wang J; Zeng J; Chen Z
BMC Cancer; 2019 Jul; 19(1):717. PubMed ID: 31324163
[TBL] [Abstract][Full Text] [Related]
40. Altered MicroRNA Expression Is Associated with Tumor Grade, Molecular Background and Outcome in Childhood Infratentorial Ependymoma.
Zakrzewska M; Fendler W; Zakrzewski K; Sikorska B; Grajkowska W; Dembowska-Bagińska B; Filipek I; Stefańczyk Ł; Liberski PP
PLoS One; 2016; 11(7):e0158464. PubMed ID: 27390862
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
